^
Association details:
| Biomarker: | TIGIT overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
TIGIT expression and outcomes in pembrolizumab treated patients with NSCLC.
Published date:
05/25/2023
Excerpt:
TIGIT high patients from the NSCLC RC demonstrated significantly higher OS (median OS = 44 months; p = 0.01) and PFS (median PFS = 35 months; p = 0.006) compared the TIGIT low patients (median OS = 23 months; median PFS = 18 months). TIGIT high cases had significantly (ORR = 60%, p = 0.001) improved response to pembrolizumab compared to TIGIT low cases (ORR = 39%)....TIGIT expression is strongly associated with proliferation and suggests improved outcomes for NSCLC cancer patients treated with an ICI therapy.
DOI:
10.1200/JCO.2023.41.16_suppl.e21110
